vs
ADAMAS TRUST, INC.（ADAM）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
ADAMAS TRUST, INC.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.2倍（$43.2M vs $35.5M），ADAMAS TRUST, INC.净利率更高（124.0% vs -304.2%，领先428.2%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 61.6%），ADAMAS TRUST, INC.自由现金流更多（$125.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 55.5%）
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ADAM vs RXRX — 直观对比
营收规模更大
ADAM
是对方的1.2倍
$35.5M
营收增速更快
RXRX
高出620.1%
61.6%
净利率更高
ADAM
高出428.2%
-304.2%
自由现金流更多
ADAM
多$173.2M
$-47.3M
两年增速更快
RXRX
近两年复合增速
55.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.2M | $35.5M |
| 净利润 | $53.5M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 124.0% | -304.2% |
| 营收同比 | 61.6% | 681.7% |
| 净利润同比 | 270.5% | 39.6% |
| 每股收益（稀释后） | $0.45 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADAMRXRX
| Q4 25 | $43.2M | $35.5M | ||
| Q3 25 | $36.6M | $5.2M | ||
| Q2 25 | $36.4M | $19.2M | ||
| Q1 25 | $33.1M | $14.7M | ||
| Q4 24 | $26.7M | $4.5M | ||
| Q3 24 | $20.2M | $26.1M | ||
| Q2 24 | $19.0M | $14.4M | ||
| Q1 24 | $17.9M | $13.8M |
净利润ADAMRXRX
| Q4 25 | $53.5M | $-108.1M | ||
| Q3 25 | $44.8M | $-162.3M | ||
| Q2 25 | $8.5M | $-171.9M | ||
| Q1 25 | $42.2M | $-202.5M | ||
| Q4 24 | $-31.4M | $-178.9M | ||
| Q3 24 | $42.8M | $-95.8M | ||
| Q2 24 | $-15.6M | $-97.5M | ||
| Q1 24 | $-57.9M | $-91.4M |
毛利率ADAMRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率ADAMRXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | 11.7% | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | -119.0% | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | -124.7% | -697.4% | ||
| Q1 24 | -448.8% | -698.4% |
净利率ADAMRXRX
| Q4 25 | 124.0% | -304.2% | ||
| Q3 25 | 122.5% | -3135.3% | ||
| Q2 25 | 23.4% | -894.2% | ||
| Q1 25 | 127.4% | -1373.3% | ||
| Q4 24 | -117.5% | -3935.5% | ||
| Q3 24 | 211.7% | -367.5% | ||
| Q2 24 | -81.9% | -676.6% | ||
| Q1 24 | -324.1% | -662.4% |
每股收益（稀释后）ADAMRXRX
| Q4 25 | $0.45 | $-0.17 | ||
| Q3 25 | $0.36 | $-0.36 | ||
| Q2 25 | $-0.04 | $-0.41 | ||
| Q1 25 | $0.33 | $-0.50 | ||
| Q4 24 | $-0.46 | $-0.56 | ||
| Q3 24 | $0.36 | $-0.34 | ||
| Q2 24 | $-0.29 | $-0.40 | ||
| Q1 24 | $-0.75 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.3M | $743.3M |
| 总债务越低越好 | $735.8M | $9.6M |
| 股东权益账面价值 | $1.4B | $1.1B |
| 总资产 | $12.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.52× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ADAMRXRX
| Q4 25 | $210.3M | $743.3M | ||
| Q3 25 | $185.3M | $659.8M | ||
| Q2 25 | $160.4M | $525.1M | ||
| Q1 25 | $177.1M | $500.5M | ||
| Q4 24 | $167.4M | $594.4M | ||
| Q3 24 | $195.1M | $427.6M | ||
| Q2 24 | $235.5M | $474.3M | ||
| Q1 24 | $226.9M | $296.3M |
总债务ADAMRXRX
| Q4 25 | $735.8M | $9.6M | ||
| Q3 25 | $766.6M | $11.9M | ||
| Q2 25 | $653.0M | $14.2M | ||
| Q1 25 | $654.4M | $16.4M | ||
| Q4 24 | $573.2M | $19.0M | ||
| Q3 24 | $699.4M | $20.5M | ||
| Q2 24 | $800.7M | $22.9M | ||
| Q1 24 | $1.0B | — |
股东权益ADAMRXRX
| Q4 25 | $1.4B | $1.1B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.4B | $919.1M | ||
| Q1 25 | $1.4B | $933.9M | ||
| Q4 24 | $1.4B | $1.0B | ||
| Q3 24 | $1.4B | $524.6M | ||
| Q2 24 | $1.4B | $584.4M | ||
| Q1 24 | $1.5B | $401.2M |
总资产ADAMRXRX
| Q4 25 | $12.6B | $1.5B | ||
| Q3 25 | $12.4B | $1.4B | ||
| Q2 25 | $10.6B | $1.3B | ||
| Q1 25 | $10.0B | $1.3B | ||
| Q4 24 | $9.2B | $1.4B | ||
| Q3 24 | $8.9B | $726.5M | ||
| Q2 24 | $8.2B | $775.9M | ||
| Q1 24 | $7.4B | $557.8M |
负债/权益比ADAMRXRX
| Q4 25 | 0.52× | 0.01× | ||
| Q3 25 | 0.55× | 0.01× | ||
| Q2 25 | 0.47× | 0.02× | ||
| Q1 25 | 0.47× | 0.02× | ||
| Q4 24 | 0.41× | 0.02× | ||
| Q3 24 | 0.48× | 0.04× | ||
| Q2 24 | 0.56× | 0.04× | ||
| Q1 24 | 0.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $125.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | 291.6% | -133.1% |
| 资本支出强度资本支出/营收 | 18.9% | 3.5% |
| 现金转化率经营现金流/净利润 | 2.50× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ADAMRXRX
| Q4 25 | $134.0M | $-46.1M | ||
| Q3 25 | $6.9M | $-117.4M | ||
| Q2 25 | $39.2M | $-76.4M | ||
| Q1 25 | $25.8M | $-132.0M | ||
| Q4 24 | $14.1M | $-115.4M | ||
| Q3 24 | $-922.0K | $-59.2M | ||
| Q2 24 | $-993.0K | $-82.2M | ||
| Q1 24 | $-13.1M | $-102.3M |
自由现金流ADAMRXRX
| Q4 25 | $125.9M | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | $-10.6M | $-116.7M | ||
| Q3 24 | $-8.6M | $-63.8M | ||
| Q2 24 | $-8.6M | $-83.4M | ||
| Q1 24 | $-19.1M | $-109.0M |
自由现金流率ADAMRXRX
| Q4 25 | 291.6% | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | -39.6% | -2567.7% | ||
| Q3 24 | -42.3% | -244.6% | ||
| Q2 24 | -44.9% | -578.5% | ||
| Q1 24 | -107.0% | -789.9% |
资本支出强度ADAMRXRX
| Q4 25 | 18.9% | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | 92.3% | 28.6% | ||
| Q3 24 | 37.7% | 17.5% | ||
| Q2 24 | 39.7% | 8.2% | ||
| Q1 24 | 33.5% | 48.2% |
现金转化率ADAMRXRX
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 4.59× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
RXRX
暂无分部数据
